Peripheral Nerve Responses to Focal Vibration and Implications in Pain and Mobility for Patients With Diabetic Peripheral Neuropathy
- Conditions
- Diabetic Peripheral Neuropathy
- Interventions
- Device: Focal vibration therapy
- Registration Number
- NCT05041816
- Lead Sponsor
- University of Oklahoma
- Brief Summary
The purpose of this study is to characterize the changes in peripheral nerve functions (sensory and motor) in patients with diabetic peripheral neuropathy, and examine the relations between the changes in nerve functions and changes in pain and mobility using focal vibration.
- Detailed Description
Peripheral nerve impairments are highly prevalent in patients with diabetic peripheral neuropathy (DPN) and are associated with pain and poor mobility. While peripheral sensorimotor nerve function is implicated in neuropathy, the mechanism associated with both pain and mobility is not well understood. Even less understood is the interplay between, and responses to, sensory and motor fibers of the affected peripheral nerve. In our previous study, focal vibration (FV) was effective in reducing pain and improving mobility for only a subgroup of participants with DPN. Because FV stimulates both motor and sensory peripheral nerve fibers, when combined with nerve conduction testing, it offers a unique opportunity to study both the sensory and motor peripheral nerve performance and their contribution to pain and mobility in patients with DPN. We are proposing a single group, repeated measured study to: characterize the changes in sensory and motor peripheral nerve functions; examine the association(s) between these changes and changes in pain and mobility, using FV. If successful, this study will provide us with a better understanding of the role played by sensory and motor nerve impairments in pain and mobility for DPN, and support larger clinical studies to optimize nerve function performance and the FV parameters. We will also explore how changes in the peripheral nerve function associate with severity of DPN.
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
- Diagnosis of diabetes for at least one year;
- Diabetic peripheral neuropathy as defined by failure to sense the 5.07 (10g) monofilament test in one or more of the six sites tested;
- Age 45-80 years old;
- Able to ambulate independently without assistive devices (e.g., walker or crutches) for 30 feet;
- No evidence of neurological (other than peripheral neuropathy) or orthopedic conditions;
- Able to understand English instructions;
- Have normal or corrected vision.
- With other non-diabetic causes of neuropathy by history;
- Symptomatic peripheral vascular disease, joint pain, swelling and/or limited range of motion in the lower extremities that interfere with walking;
- Other systemic or local diseases that could interfere with walking assessment
- Amputation in the lower extremities;
- Clinically diagnosed with dementia greater than mild (screened using Montreal Cognitive Assessment (MOCA) <24)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Focal vibration group Focal vibration therapy The Myovolt device used in our previous study will be used for focal vibration delivery during week three to six. Participants will wear Myovolt secured by an elastic band, at a location based on therapist and participants preference. During the four weeks of the FV therapy, participants will be asked to use the Myovolt device for up to 0.5-hour per session (each site 10 minutes per session, with one-minute intersession between sites), once in the morning and once in the evening each day, for five days a week. The dosing paradigm was chosen based on the safety and potential effectiveness of the FV therapy, and our preliminary study.
- Primary Outcome Measures
Name Time Method Changes in CMAP Change from Baseline CMAP measures every 2 weeks for up to 6 weeks The peroneal compound muscle action potential (CMAP)
Changes in TUG Change from Baseline TUG scores every 2 weeks for up to 6 weeks Timed Up and Go (TUG) test
Changes in NTSS-6 Change from Baseline NTSS-6 scores every 2 weeks for up to 6 weeks The Neuropathy Total Symptom Score - 6-items (NTSS-6), which quantifies frequency and intensity of aching, burning, prickling and lancinating pain, numbness, and allodynia in patients' feet and legs.
Changes in NSS Change from Baseline NSS scores every 2 weeks for up to 6 weeks The Neuropathy Symptom Score (NSS), which quantifies symptoms of motor, sensory, and autonomic deficits.
Changes in BPI-DPN Change from Baseline BPI-DPN scores every 2 weeks for up to 6 weeks The Brief Pain Inventory Short Form for Diabetic Peripheral Neuropathy
Changes in NIS Change from Baseline NIS scores every 2 weeks for up to 6 weeks The Neurologic Impairment Score (NIS), composed of a sensory sub-score (which evaluates sensory perceptions to touch, prickling pain, vibration, joint position, and 1- and 10-g monofilaments in the upper and lower extremities) and a motor sub-score (which evaluates cranial nerves, muscle strength, muscle wasting, and deep tendon reflexes in the upper and lower extremities).
Changes in NCV Change from Baseline NCV measures every 2 weeks for up to 6 weeks The peroneal motor nerve conduction velocity
Changes in SNAP Change from Baseline SNAP measures every 2 weeks for up to 6 weeks The digital sensory nerve action potentials
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University of Oklahoma Health Sciences Center
🇺🇸Oklahoma City, Oklahoma, United States